We next solve the discrete optimization problem to identify sequential combination therapies utilizing imatinib, dasatinib and nilotinib to optimally treat CML patients with preexisting BCR-ABL mutations. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.